Erasmus MC

erasmusmc.nl

Erasmus MC is the largest and most versatile of the eight university medical centers in the Netherlands. At Erasmus MC you create your own opportunities. A conscious choice for work that matters, both nationally and internationally, at the heart of our multicultural home base of Rotterdam. Working from the heart. Together with people, for people.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

GT MOLECULAR, RAPIDLY EXPANDING MOLECULAR DIAGNOSTICS BIOTECH, LAUNCHES TWO HIGHLY SENSITIVE TESTS FOR THE DANGEROUS UK VARIANT OF SARS-COV-2

GT Molecular | January 13, 2021

news image

GT Molecular, a quickly extending sub-atomic diagnostics biotech, has dispatched two profoundly delicate tests for the risky UK Variant of SARS-CoV-2 (B.1.1.7). These tale examines expand upon GT Molecular's clinical foundation and technology for profoundly exact and solid qPCR and advanced PCR recognition of SARS-CoV-2 virus and are offered in two formats. The fee-for-service testing of wastewater for the presence of SARS-CoV-2 and the variations available for use furnishes n...

Read More

Industrial Impact

PROVIDENCE THERAPEUTICS SIGNS LICENSING AGREEMENT WITH SICKKIDS FOR IMMUNOTARGETING TECHNOLOGY

Providence Therapeutics | July 13, 2022

news image

Providence Therapeutics, Canada's premier mRNA medicines company, is pleased to announce that it has entered into an exclusive licensing agreement with The Hospital for Sick Children of Toronto, ON, for an immunotargeting technology platform. This platform provides an innovative approach to generating adjuvant-free vaccines and works by targeting Antigen Presenting Cells of the immune system via the MHC Class II molecules on their surface. This can result in an enhanced immune response to an...

Read More

Cell and Gene Therapy

ANUVA ANNOUNCES SERIES A CLOSURE AND ENTERS INTO A STRATEGIC PARTNERSHIP WITH HELIX

Anuva and Helix | August 30, 2022

news image

Anuva enters into its next stage of growth focused on creating the most diverse Genomic Bio / Data Bank at scale. To enable this, Anuva is entering into a global strategic partnership with Helix, the leading population genomics and viral surveillance company in the United States. Anuva will be generating new knowledge on health and disease, directly applicable to treatments, on diverse under-represented populations to advance drug discovery through the identification of novel targ...

Read More

Industrial Impact

RESILIENCE PARTNERS WITH A MAJOR PHARMACEUTICAL COMPANY FOR STRATEGIC BIOMANUFACTURING

Resilience | February 20, 2023

news image

National Resilience, Inc. (Resilience), a manufacturing company with a technology-focused mission to improve access to complex medications, recently announced a 10-year biomanufacturing partnership with a top pharmaceutical company for its portfolio of services in process and analytical development, drug substance manufacturing, and drug product manufacturing. The extensive agreement covers prospective biologic, vaccine, nucleic acid, cell, and gene therapy manufacturing. Resili...

Read More
news image

Medical

GT MOLECULAR, RAPIDLY EXPANDING MOLECULAR DIAGNOSTICS BIOTECH, LAUNCHES TWO HIGHLY SENSITIVE TESTS FOR THE DANGEROUS UK VARIANT OF SARS-COV-2

GT Molecular | January 13, 2021

GT Molecular, a quickly extending sub-atomic diagnostics biotech, has dispatched two profoundly delicate tests for the risky UK Variant of SARS-CoV-2 (B.1.1.7). These tale examines expand upon GT Molecular's clinical foundation and technology for profoundly exact and solid qPCR and advanced PCR recognition of SARS-CoV-2 virus and are offered in two formats. The fee-for-service testing of wastewater for the presence of SARS-CoV-2 and the variations available for use furnishes n...

Read More
news image

Industrial Impact

PROVIDENCE THERAPEUTICS SIGNS LICENSING AGREEMENT WITH SICKKIDS FOR IMMUNOTARGETING TECHNOLOGY

Providence Therapeutics | July 13, 2022

Providence Therapeutics, Canada's premier mRNA medicines company, is pleased to announce that it has entered into an exclusive licensing agreement with The Hospital for Sick Children of Toronto, ON, for an immunotargeting technology platform. This platform provides an innovative approach to generating adjuvant-free vaccines and works by targeting Antigen Presenting Cells of the immune system via the MHC Class II molecules on their surface. This can result in an enhanced immune response to an...

Read More
news image

Cell and Gene Therapy

ANUVA ANNOUNCES SERIES A CLOSURE AND ENTERS INTO A STRATEGIC PARTNERSHIP WITH HELIX

Anuva and Helix | August 30, 2022

Anuva enters into its next stage of growth focused on creating the most diverse Genomic Bio / Data Bank at scale. To enable this, Anuva is entering into a global strategic partnership with Helix, the leading population genomics and viral surveillance company in the United States. Anuva will be generating new knowledge on health and disease, directly applicable to treatments, on diverse under-represented populations to advance drug discovery through the identification of novel targ...

Read More
news image

Industrial Impact

RESILIENCE PARTNERS WITH A MAJOR PHARMACEUTICAL COMPANY FOR STRATEGIC BIOMANUFACTURING

Resilience | February 20, 2023

National Resilience, Inc. (Resilience), a manufacturing company with a technology-focused mission to improve access to complex medications, recently announced a 10-year biomanufacturing partnership with a top pharmaceutical company for its portfolio of services in process and analytical development, drug substance manufacturing, and drug product manufacturing. The extensive agreement covers prospective biologic, vaccine, nucleic acid, cell, and gene therapy manufacturing. Resili...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us